Platelet Dopamine Uptake in Huntington’s Chorea and Gilles de la Tourette’s Syndrome: Effect of Haloperidol

ROGER F. BUTTERWORTH, MICHEL GONCE, AND ANDRÉ BARBEAU

SUMMARY: Uptake of \(^{14}\text{C}\)-dopamine by human platelets has been studied in two diseases, namely Gilles de la Tourette’s syndrome and Huntington’s chorea, in which abnormal metabolism of dopamine has been implicated. Platelets from untreated Huntington’s chorea patients showed a small increase in \(K_m\) and \(V_{max}\); platelets from patients in all other groups showed an uptake identical with the controls. Haloperidol (\(10^{-5}\text{M}\)) was also shown to be a strong non-competitive inhibitor of \(^{14}\text{C}\)-DA uptake by platelets. This property is probably unrelated to the drugs’ action in ameliorating the symptoms of Huntington’s chorea which is likely related to the increase in cholinergic neuronal activity produced by neuroleptic blockade of dopamine receptors.

INTRODUCTION

Transport of biogenic amines by human platelets shows many similarities to synaptosomal preparations (Paasonen, 1973). In addition, platelet amine uptake is abnormal in Down’s syndrome (Lott et al., 1972), Duchenne muscular dystrophy (Murphy et al., 1973) and Parkinson’s disease (Barbeau et al., 1975). The decreased accumulation of dopamine by Parkinsonian patients’ platelets offered the first evidence that the dopamine defect was of a more generalized nature (Barbeau et al., 1975). The present study was undertaken to look for similar deficits in two other diseases in which disordered dopamine metabolism has been implicated, namely Huntington’s chorea and Gilles de la Tourette’s syndrome. Aminoff et al. (1974) reported the plasma uptake of dopamine and serotonin is significantly elevated in patients with Huntington’s chorea.

SUBJECTS, MATERIALS AND METHODS

Subjects
A. Controls
Eleven normal volunteer subjects of either sex were chosen with ages ranging from 17 to 45 yr. One control subject was always studied at the same time as a patient.

B. Huntington’s Chorea patients
Six patients with varying degrees of severity of the disease, ages ranging from 21 to 53 yr. were divided into two groups of 3; group 1 patients had been treated with haloperidol, group 2 patients had not been treated with haloperidol.
C. Gilles de la Tourette’s patients
Five patients with varying degrees of severity of the disease and age range 20 to 43 yr. were studied.

Materials

\[^{14}C\]-dopamine (\[^{14}C\]-2-C-ethylamine)-(dopamine), specific activity 50 mci/m.m柳 was obtained from the Radiochemical Centre, Amsterdam. Dopamine (3 hydroxytyramine) hydrochloride was purchased from Calbiochem. Haloperidol (Haldol) was purchased from McNeil Laboratories, Don Mills, Ontario, Canada.

Methods

Preparation of platelet-rich plasma, platelet count and uptake of \[^{14}C\]-dopamine by platelets was done as previously described (Barbeau et al., 1975).

Kinetics of uptake of \[^{14}C\]-dopamine by platelets

1 ml samples of platelet-rich plasma were incubated at 37°C for 30 min. with \[^{14}C\]-DA of the following concentrations: 10.0 x 10^-5M., 2.0 x 10^-5M., 1.0 x 10^-5M., and 0.5 x 10^-5M. Platelets were then isolated by centrifugation (8000 G., 5 min., 4°C), disrupted by sonification and assayed for radioactivity as previously described (Barbeau et al., 1975). The kinetics of uptake of dopamine by the platelet were evaluated by relating the velocity of uptake of this amine to its concentration in the medium by the method of Lineweaver and Burk (1934). The influence of haloperidol (10^-5 M) on the platelet uptake of \[^{14}C\]-dopamine was studied by including this compound at the appropriate concentration in the incubation medium.

RESULTS

Human platelets were found to accumulate dopamine when incubated in plasma containing \[^{14}C\]-labelled dopamine, as shown in Table 1. The Gilles de la Tourette’s patients’ platelets showed a tendency toward more rapid accumulation of dopamine at initial times, but these differences were not significant as analysed by Student t test. Huntington’s chorea patients’ platelets were found to take up dopamine at the same rates as age-matched controls.

When platelets from normal individuals were incubated in plasma containing \[^{14}C\]-dopamine, the rate of uptake was as shown in Figure 1, as studied by Lineweaver and Burk kinetic analysis. From Figure 1, the mean value for Km was 3.7 x 10^-5M. DA. Ranges of values for the control population studied by us were found to be 2.22 - 5.10 x 10^-5M.

When haloperidol (10^-5 M.) was included in the incubation mixture, a strong non-competitive inhibition was seen, as shown in Figure 1. K_i for inhibition, as obtained by Dixon plot was 1.0 x 10^-5M.

When the kinetics of uptake of \[^{14}C\]-dopamine by platelets were analysed by the method of Lineweaver and Burk (1934) for controls and patients, values for Km and Vmax. were obtained and are shown in Table 2.

Although controls and patients do not show any major differences in Km and Vmax., it is interesting to note that there is a tendency by platelets of untreated Huntington’s chorea patients to show an increased Vmax. and Km compared to those patients receiving haloperidol for treatment of the disease.

DISCUSSION

The primary defect in Parkinson’s disease is a massive degenerative loss of the dopaminergic neurons of the nigro-striatal pathway. These neurons appear to be present in normal amounts in the basal ganglia in Huntington’s chorea (Barbeau, 1975). Loss of GABA-containing neurons from the basal ganglia in Huntington’s chorea cannot explain the extrapyramidal movement disorder seen in this disease since a similar loss of GAD activity occurs in the basal ganglia tissue of Parkinson’s disease and Alzheimer’s presenile dementia. A more likely explanation might involve the interrelationship between dopamine and acetylcholine in these two diseases. There is good evidence that choreiform movements are associated with an enhanced receptor response to dopamine in extrapyramidal structures and, furthermore, the most effective drugs reducing choreiform movements are catecholamine depleting agents such as reserpine and dopamine-receptor antagonists like chlorpromazine and haloperidol (Barbeau, 1973).

It has been reported that the uptake of dopamine by platelet-rich plasma from patients with Huntington’s chorea was significantly greater than controls (Aminoff et al., 1974; McLean and Nihei, 1977), while the uptake in Gilles de la Tourette’s syndrome has not previously been reported. The present study shows that the platelet uptake of dopamine in the two diseases is not different from the controls. This is in contrast to Parkinsonian patients

| TABLE 1 |
| UPTAKE OF DOPAMINE BY HUMAN PLATELETS |
| N | UPTAKE n mol. \[^{14}C\]-DA PER \(10^9\) PLATELETS (± S.E.M.) |
|---|---|---|---|---|---|
| | 10 min. | 60 min. | 90 min. | 120 min. | 180 min. |
| CONTROLS | 11 | 7.43 ± 0.79 | 39.19 ± 2.72 | 49.50 ± 3.0 | 54.72 ± 2.42 | 56.37 ± 2.62 |
| HUNTINGTON’S CHOREA | 6 | 8.76 ± 0.82 | 38.13 ± 3.51 | 53.07 ± 4.27 | 57.98 ± 6.12 | 59.61 ± 8.52 |
| GILLES DE LA TOURETTE’S | 5 | 9.11 ± 1.31 | 44.64 ± 5.71 | 48.41 ± 8.12 | 55.49 ± 4.73 | 56.69 ± 8.70 |
who have a markedly decreased platelet dopamine uptake (Barbeau et al., 1975). It appears that altered uptake of dopamine cannot be used with reliability as a predictive test as previously suggested (McLean and Nihei, 1977).

Kinetics of the accumulation of dopamine by the human platelet were studied by the method of Lineweaver and Burk (1934). A mean Km value for platelets from normal volunteers of $3.70 \times 10^{-5}$ M. DA was obtained with a range of values from $2.22 - 5.10 \times 10^{-5}$ M. DA. This is in good general agreement with the value for Km of $6.7 \times 10^{-5}$ M. DA published by Solomon et al. (1970) using a slightly modified technique. In vivo studies show (Figure 1) that haloperidol ($10^{-5}$ M.) produces a strong non-competitive inhibition of platelet dopamine uptake. This in vivo action of haloperidol is likely unrelated to the drug's action in producing improvement of the symptoms of Huntington's chorea or Gilles de la Tourette's syndrome. Previously, other neuroleptics, including chlorpromazine, have been shown to inhibit non-competitively the uptake of dopamine by synaptosomes from corpus striatum (Horn et al., 1971), while another study (Solomon et al., 1970) reported that haloperidol ($10^{-4}$ M.) produced a 90% inhibition of dopamine uptake by human blood platelets.

It is difficult to reconcile the antichorea action of haloperidol with these observations. It has been suggested (Kehr et al., 1972) that haloperidol acts both pre and post synaptically, while the drug's action in ameliorating the symptoms of Huntington's chorea and Gilles de la Tourette's syndrome is generally considered to be a result of post-synaptic receptor blockade. Perhaps other neuroleptics having a more purely post-synaptic action (such as pimozide) may be more useful in the treatment of these disorders. Indeed, Fog and Pakkenberg (1970) reported that pimozide combined with tetrabenazine improved chorea in 9 out of 12 patients. Improvement using pimozide alone in 2 patients could not, however, be found by others (Lal et al., 1973).

Bird and Iversen (1974) reported that choline acetyltransferase activity was decreased in brain tissue of patients dying with Huntington's chorea. This decreased activity appeared to have been restored in patients who were treated with neuroleptics. Neuroleptics blockade of dopamine receptors has been shown to enhance acetylcholine turnover (Stadler et al., 1973); the mechanism of this action, however, remains to be fully understood. It is of interest to note that beneficial results have been observed in chorea and tardive dyskinesia by treatment with choline (Davis et al., 1976; Growdon et al., 1977).

![Figure 1](https://example.com/figure1.png)

**Figure 1**—Kinetics of inhibition of uptake of dopamine by haloperidol in human platelets. Platelets were incubated in the presence of (•) and in the absence of (O) haloperidol $10^{-6}$ M.

### Table 2

**Kinetics of Uptake of $^{14}$C-Dopamine by Platelets**

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>MEAN AGE (YR.)</th>
<th>$V_{max.}$ n mol. $^{14}$C-DA PER $10^6$ PLATELETS PER 30 MIN.</th>
<th>Km ($x 10^{-5}$ M. DA)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTROLS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>27.3</td>
<td>0.97 ± 0.08</td>
<td>3.70 ± 0.29</td>
</tr>
<tr>
<td><strong>PATIENTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gilles de la Tourette</td>
<td>5</td>
<td>28.6</td>
<td>0.77 ± 0.11</td>
<td>3.80 ± 0.91</td>
</tr>
<tr>
<td>Huntington's Chorea</td>
<td>6</td>
<td>32.3</td>
<td>1.02 ± 0.12</td>
<td>4.15 ± 0.84</td>
</tr>
<tr>
<td>Haloperidol Treated</td>
<td>3</td>
<td>31.7</td>
<td>0.98, 0.95, 0.52</td>
<td>3.05, 3.68, 1.42</td>
</tr>
<tr>
<td>Untreated</td>
<td>3</td>
<td>33.0</td>
<td>1.16, 1.35, 1.18</td>
<td>7.54, 5.14, 4.07</td>
</tr>
</tbody>
</table>

*Butterworth et al.*

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 14 Oct 2018 at 22:42:15, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0317167100025130
ACKNOWLEDGEMENTS

These studies were supported in part by grants from the Medical Research Council of Canada (MT-4938), the United Parkinson Foundation and the W. Garfield Weston Foundation.

The authors would like to express their gratitude to Mrs. France Landreville and Miss Francine Bélanger for their technical assistance and to Mrs. Monique Savard for typing the manuscript.

REFERENCES


Platelet Dopamine Uptake